Download resume here:

BRYAN CURRY

Vice President, Quality Assurance & Regulatory Affairs Katy, Texas | 210.316.3950 | [email protected]

EXECUTIVE PROFILE: Strategic Quality and Regulatory Affairs Executive with over 20 years of leadership in OEM and Contract Manufacturing for the medical device industry. Proven track record in transforming organizational culture, driving fundamental compliance improvements, and managing complex global business units. Dual RAPS certified in Medical Device and Pharmaceutical Regulatory Affairs with deep expertise in FDA, EUMDR, and ISO 13485 standards.

🛠️ CORE COMPETENCIES

Leadership & Strategy	Regulatory & Compliance
Strategic Planning & M&A Integration	ISO Lead Auditor & 483/Warning Letters
Multi-Site Global Operations	FDA 21CFR820, EUMDR, CMDR
Organizational Restructuring	Remote Regulatory Assessments
Six Sigma Black Belt (DMAIC)	Routine, PMA, PAI Inspection Management

💼 PROFESSIONAL EXPERIENCE

VIANT MEDICAL, INC. Vice President, Quality Assurance and Regulatory Affairs | November 2012 – Present

Strategic Global Oversight

Global Footprint: Provide executive leadership and accountability for 14 facilities across 7 geographic locations, including the United Kingdom, Costa Rica, and Mexico (Tijuana).
Business Unit Management: Directly manage the Quality and Regulatory scope for the Medical Device, OrthoPlastics, and Combo Device Business Units.
Lifecycle Management: Maintain executive oversight for all Design & Development (D&D) and Advanced Plastics Manufacturing centers.
Organizational Design: Restructured the global quality organization to align staff strengths with evolving business focus and customer requirements.
Liaison: Serve as the primary liaison for global government agencies, including the FDA, US EPA, and International Notified Bodies.

Operational Impact & Compliance Excellence

Inspection Success: Managed 11 FDA inspections (including PAI and Combination Device), achieving zero findings in 5 instances.
Metric Improvement: Engineered a >78% reduction in total complaints and >66% reduction in nonconformances (2019–2025).